Tarceva set for first line treatment

Roche’s oral lung cancer treatment Tarceva (erlotinib) has been approved by the Korea Food and Drug Administration as a first line treatment for people with newly diagnosed advanced non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) activating mutations lived without their disease getting worse (progression-free survival or PFS), according to its Korean unit Roche K...